louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05951881: Comparative Study of the Performance of Drug Anamneses in an Emergency Department
Official title: Comparative Study Between a Pharmacy Technician and a Pharmacist in the Performance of Medication Anamneses in Emergency Departments: a Skills Validation Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Medication Adherence
Lead sponsor: Grand Hôpital de Charleroi
Sponsor class: OTHER
First posted: 2023-07-19
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: This research is aimed at patients admitted to the emergency department of the Saint-Joseph site.

All patients over 18 years of age who are capable of giving informed consent and who are taking several medications prior to their admission to the emergency department.

Brief summary: After the first medical history by the nurse and the emergency physician, the pharmacist and the pharmacy assistant take a detailed history of the patient's medications separately.

After checking with the patient's reference pharmacy, the pharmacist and pharmacy assistant compare their results.


Eligibility criteria: Inclusion Criteria:

* Admission to the emergency care unit
* Over 18 years old
* Giving consent to participate

Exclusion Criteria:

* Patients who do not take medication daily
* Unconscious patients

Primary outcomes:
measure: Percentage of identical medication anamneses between pharmacist and pharmacy assistant
timeFrame: immediately after admission to the emergency department
Secondary outcomes:
Other outcomes:
Locations:
city: Charleroi
country: Belgium
facility: GHdC
state: Hainaut
Study officials:
affiliation: Grand Hôpital de Charleroi
name: Laurence Rosart, Pharmacist
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04638881: Magnesium for Peroral Endoscopic Myotomy
Official title: A Prospective, Randomized, Double-blind, Placebo-controlled Trial of the Effects of Magnesium Sulfate on Postoperative Esophageal Spasm-associated Pain Following Peroral Endoscopic Myotomy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Esophageal Spasm
Lead sponsor: Stanford University
Sponsor class: OTHER
First posted: 2020-11-20
Enrollment: 92
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Postoperative pain after peroral endoscopic myotomy occurs due to involuntary esophageal smooth muscle spasms. Magnesium has antispasmodic properties as a smooth muscle relaxant. This study hypothesizes that among patients having peroral endoscopic myotomy, magnesium will decrease postoperative esophgeal pain as measured by the esophageal symptoms questionnaire, while decreasing perioperative opioid requirements.


Eligibility criteria: Inclusion Criteria:

- Planned peroral endoscopic myotomy procedure

Exclusion Criteria:

* cannot give consent
* patients who are clinically unstable and/or require urgent/emergent intervention
* previous esophageal myotomy
* preexisting hypermagnesemia
* end-stage renal disease
* neuromuscular disease, including but not limited to Guillain-Barre syndrome, myasthenia gravis, congenital myopathy, and muscular dystrophy
* preexisting heart failure
* severe ventricular systolic dysfunction (left or right ventricle)

Primary outcomes:
measure: Esophageal Symptoms Questionnaire Score (ESQ)
timeFrame: 0 hours postoperatively
Secondary outcomes:
measure: Esophageal Symptoms Questionnaire Score (ESQ)
timeFrame: 24 hours postoperatively
measure: Postoperative Opioid Consumption
timeFrame: From extubation to 24 hours after extubation
measure: Postoperative Day 1 Opioid Consumption
timeFrame: From 24 hours after extubation to 48 hours after extubation
measure: Average Visual Acuity Score Pain Score in Postanesthesia Care Unit
timeFrame: From extubation to discharge from postanesthesia care unit (up to 4 hours)
Other outcomes:
Locations:
city: Stanford
country: United States
facility: Stanford Health Care
state: California
Study officials:
affiliation: Stanford University
name: Richard K Kim, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Stanford University
name: Joo H Hwang, MD PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Stanford University
name: Ban C Tsui, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06240481: Clinical Research Study to Assess the Efficacy of Two Brushing Regimens
Official title: Study to Assess the Efficacy of Two Brushing Regimens in the Reduction of Dental Plaque and Aid of Gum Problems
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE3
Conditions: Dental Plaque
Gingivitis
Keywords: plaque
gingivitis
Loe and Silness Gingival Index
Quigley and Hein Plaque Index
Lead sponsor: Colgate Palmolive
Sponsor class: INDUSTRY
First posted: 2024-02-05
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The objective of this twelve-week clinical research study is to assess the efficacy of two brushing regimens: 1) toothpaste with mouthwash containing sodium fluoride/zinc and manual toothbrush as compared to 2) regular fluoride toothpaste and manual toothbrush in the reduction of dental plaque and aid of gum problems.


Eligibility criteria: Inclusion Criteria:

* Signed Informed Consent Form.
* Male and female subjects aged 18-70 years, inclusive.
* Availability for the twelve-week duration of the clinical research study.
* Good general health based on the opinion of the study investigator
* Minimum of 20 permanent natural teeth (excluding third molars).
* Initial gingivitis index of at least 1.0 as determined by the use of the Loe and Silness Gingival Index.
* Initial plaque index of at least 1.5 as determined by the use of the Quigley and Hein Plaque Index (Turesky Modification)

Exclusion Criteria:

* Presence of orthodontic appliances.
* Presence of partial removable dentures.
* Tumor(s) of the soft or hard tissues of the oral cavity.
* Moderate and/or advanced periodontal disease, rampant caries, or any condition that the dental examiner considers exclusionary from the study.
* Five or more carious lesions requiring immediate restorative treatment.
* Antibiotic use any time during the one-month period prior to entry into the study. -Participation in any other clinical study or test panel within the one month prior to entry into the study.
* Dental prophylaxis during the past two weeks prior to baseline examinations.
* History of allergies to oral care/personal care consumer products or their ingredients. -On any prescription medicines that might interfere with the study outcome.
* An existing medical condition that prohibits eating and/or drinking for periods up to 4 hours.
* History of alcohol and/or drug abuse.
* Self-reported pregnancy and/or lactating subjects.

Primary outcomes:
measure: Quigley and Hein Plaque Index
timeFrame: Baseline, 3 weeks, 6 week & 12 weeks
measure: Loe and Silness Gingival Index
timeFrame: Baseline, 3 weeks, 6 week & 12 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Manresa
country: Spain
facility: Clinica Dental Dr. Sitges
Study officials:
affiliation: Clinica Dental Dr. Sitges Carretera de Cardona
name: Augusto R Elias-Boneta, DMD, MSD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04668781: Improvement of Care of Patients Undergoing Pancreaticoduodenectomy
Official title: Improvement of Care of Patients Undergoing Pancreaticoduodenectomy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pancreatic Diseases
Pancreas Cancer
Keywords: pancreaticoduodenectomy
fluid therapy
enhanced recovery after surgery (ERAS)
postoperative complications
Lead sponsor: Helsinki University Central Hospital
Sponsor class: OTHER
Collaborators: name: University of Helsinki
First posted: 2020-12-16
Enrollment: 92
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study is a randomised controlled trial comparing the effectivity and impact of epidural analgesia and wound catheter analgesia in patients undergoing pancreaticoduodenectomy. The aim of the study is to examine whether there are a difference in perioperative fluid therapy and complication rates between the patients in epidural and wound catheter groups.

Detailed description: All patients undergoing pancreaticoduodenectomy in Helsinki University Hospital are recruited in the study. Patients meeting the inclusion criteria and giving consent to participate the study will be randomised to whether epidural analgesia group or wound catheter analgesia group. Both groups receive additional analgesia with intravenous PCA-oxycodone (patient controlled analgesia).

Eligibility criteria: Inclusion Criteria:

* age 18 years or over
* patients who undergo pancreaticoduodenectomy

Exclusion Criteria:

* patients to whom are made a major vascular reconstruction
* patients with significant comorbidities and inability to use PCA
* regural use of strong opioids or drugs preoperatively
* patients with severe chronic pain issues
* chronic atrial fibrillation
* patients who refuse to take part to the study

Primary outcomes:
measure: The norepinephrine consumption
timeFrame: Postoperative day 0
Secondary outcomes:
measure: Fluid volumes on PODs 0-4
timeFrame: Postoperative days 0-4
measure: Oxycodone consumption
timeFrame: Postoperative days 1-4
measure: Hospital length of stay
timeFrame: Postoperative days 0-60
measure: Postoperative complications
timeFrame: Postoperative days 0-90
measure: Reoperation rates
timeFrame: Postoperative days 0-90
measure: Readmission rates
timeFrame: Postoperative days 0-90
measure: Mortality
timeFrame: postoperative day 0-90
Other outcomes:
Locations:
city: Helsinki
country: Finland
facility: Helsinki University Hospital
state: HUS
Study officials:
References:
Clinical trial NCT01260610: Randomized Controlled Study of Tenofovir Plus Telbivudine Versus Monotherapy With Either Drug in HBeAg Negative Chronic Hepatitis B Patients
Official title: An Exploratory, Randomized, Controlled Study of Tenofovir Plus Telbivudine Versus Monotherapy With Either Drug Alone in HBeAg Negative Chronic Hepatitis B Patients
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Chronic Hepatitis B
Keywords: Hepatitis B, Tenofovir, Telbivudine
Lead sponsor: Institute of Liver and Biliary Sciences, India
Sponsor class: OTHER
First posted: 2010-12-15
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Combination therapies using nucleos(t)ide analogues lead to higher viral suppression although it may not be sustained for long. Also it remains unknown if combination of more potent analogues is more beneficial than individual drugs. Thus this study is carried out to determine the efficacy and safety of combination of tenofovir plus telbivudine (two most potent nucleos(t)ide analogues)versus monotherapy with either drug alone. This is a 104 week open labelled, prospective, randomized, multicentric study. The patient will receive either tenofovir, telbivudine or the combination of two drugs. After completion of 24 weeks, the non-responders (ie HBV-DNA \> 300 copies/ ml) will be switched to combination arm and will continue receiving tenofovir plus telbivudine for 104 weeks.


Eligibility criteria: Inclusion Criteria:

* HBeAg negative at screening
* Documented chronic Hepatitis B
* Treatment naive
* Compensated liver disease

Exclusion Criteria:

* Chronic Hepatitis B with Child Pugh B \& C
* HBeAg positive
* Decompensated liver disease

Primary outcomes:
measure: Efficacy of combination of telbivudine plus tenofovir vs monotherapy with either drug alone
timeFrame: 6 Months and 2 Years
Secondary outcomes:
measure: Percentage change in serum HBV DNA levels
timeFrame: Baseline and 2 Years
measure: Percentage of patients with ALT normalization
timeFrame: Baseline and 2 Years
measure: Percentage of patients with reduction in HBsAg concentration by >50%
timeFrame: Baseline and 2 Years
measure: Percentage of patients with virological breakthrough
timeFrame: 24 weeks
measure: Percentage of patients with primary treatment failure
timeFrame: 12 weeks
measure: Occurrence of adverse events
timeFrame: 2 Years
Other outcomes:
Locations:
city: New Delhi
country: India
facility: Institute of Liver & Biliary Sciences
Study officials:
affiliation: Institute of Liver & Biliary Sciences
name: Dr S. K. Sarin, MD, DM
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02915510: GMP Drink for PKU Study
Official title: Evaluating the Tolerance, Safety and Acceptability of PKU GMPro, a Whey Protein Derived Feed for the Dietary Management of Phenylketonuria in Children and Adults - a Pilot Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Phenylketonuria
Lead sponsor: Nutricia UK Ltd
Sponsor class: INDUSTRY
First posted: 2016-09-27
Enrollment: 40
Sex: ALL
Minimum age (years): 3
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: This study will evaluate the safety, gastrointestinal (GI) tolerance, acceptability and compliance of a Glycomacropeptide-based protein substitute for patients with Phenylketonuria (PKU).


Eligibility criteria: Inclusion Criteria:

* Male or female
* Over 3 years of age
* Diagnosed with classical or variant type phenylketonuria
* Have been compliant in taking at least one amino acid-based, Phe-free protein substitute, providing at least 20g protein equivalents, for at least 1 month prior to trial commencement
* Have a prescribed daily Phe allowance
* Written informed consent from patient, or from parent / carer if applicable

Exclusion Criteria:

* Currently prescribed Sapropterin or similar tetrahydrobiopterin based medication
* Pregnant or lactating
* Requiring parenteral nutrition
* Major hepatic or renal dysfunction
* Participation in other studies within 1 month prior to entry of this study
* Allergy to any of the study product ingredients, including milk protein or soya
* Investigator concern around willingness/ability of patient or parent/carer to comply with protocol requirements

Primary outcomes:
measure: Blood Phenylalanine (and other amino acids)
timeFrame: 3 points throughout 28 days
Secondary outcomes:
measure: Gastro-intestinal tolerance questionaire
timeFrame: 12/31 days
measure: Product compliance questionaire
timeFrame: 31 days
measure: Product acceptability questionnaire
timeFrame: 2/31 days
measure: Patient reproted nutrient intake (3 day food diaries)
timeFrame: 6/31 days
measure: Pateint-reported appetite (visual analogue scale)
timeFrame: 6/31 days
measure: Antropometry (hieight and weight)
timeFrame: 2/31 days
measure: Safety (Adverse events reporting)
timeFrame: 31 days
Other outcomes:
Locations:
city: London
country: United Kingdom
facility: Great Ormond Street Hospital
city: London
country: United Kingdom
facility: Guy's and St Thomas' NHS Fondation Trust
city: London
country: United Kingdom
facility: UCLH
city: Manchester
country: United Kingdom
facility: Royal Manchester Children's Hospital
city: Sheffield
country: United Kingdom
facility: Sheffield Teaching Hospital
Study officials:
affiliation: Nutricia Ltd UK
name: Rebecca Stratton, PHd
role: STUDY_DIRECTOR
References:
Clinical trial NCT00904410: Early Assessment of the Response to Neo-adjuvant Chemotherapy in Breast Cancer Patients With FDG-PET
Official title: Early Assessment of the Response to Neo-adjuvant Chemotherapy in Breast Cancer Patients With FDG-PET
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Breast Cancer
Keywords: adenocarcinoma
breast
Lead sponsor: Centre Oscar Lambret
Sponsor class: OTHER
Collaborators: name: Ministry of Health, France
First posted: 2009-05-19
Enrollment: 63
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: 18F-FDG PET, a whole-body imaging technology based on glucose metabolism, can effectively detect subclinical and clinical therapeutic responses at stages that are earlier than those detected by conventional approaches.

We propose to conduct a prospective study to evaluate early therapeutic response using 18F-FDG PET before and after the 1st cycle of neo-adjuvant chemotherapy for breast cancer patients.

Variation of 18F-FDG PET uptake is compared to clinical and echographical tumor response evaluated after 3 cycles of chemotherapy.

The purpose is to estimate the capacity of 18F-FDG PET to differentiate responder and non-responder patients.

Detailed description: Further study details as provided by Centre Oscar Lambret

Eligibility criteria: Inclusion Criteria:

* Age \> 18
* Breast cancer treated by neo-adjuvant chemotherapy (T\>2cm)
* Measurable lesions ,assessed clinically and by ultrasound
* Delay minimum between biopsy and PET: 15 days
* PS-WHO: 0

Exclusion Criteria:

* T\<2cm
* Inflammatory breast cancer (T4d)
* Diabetic patients unbalanced (glycemia\>1.40)
* Pregnant or lactating women

Primary outcomes:
measure: Variation rate of SUV(BSA max)before and after the 1st cycle of neoadjuvant chemotherapy
timeFrame: before and 3 weeks after 1st cycle
Secondary outcomes:
measure: Comparison to clinical and ultrasound assessment after the 3rd cycle of chemotherapy
timeFrame: 3 weeks after the 3rd cycle
Other outcomes:
Locations:
city: Lille
country: France
facility: Centre Oscar Lambret
Study officials:
affiliation: Centre Oscar Lambret
name: GAUTHIER Helene
role: STUDY_CHAIR
References:
Clinical trial NCT01668810: The Third Survey of Prescription Pattern of Psychotropic Drugs in China
Official title: The Third Survey on China Psychotropic Prescription for Schizophrenia, Depression and Bipolar Disorder
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Prescription
Keywords: prescription
schizophrenia
depression
bipolar disorder
Lead sponsor: Peking University
Sponsor class: OTHER
Collaborators: name: Xian-Janssen Pharmaceutical Ltd.
First posted: 2012-08-20
Enrollment: 7000
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: schizophrenia, depression and bipolar disorder patients

Brief summary: The investigators aimed to examine the psychotropic prescription pattern in China.


Eligibility criteria: Inclusion Criteria: aged 18-65, inpatient or outpatient, Patient must be willing and able to give written informed consent,the patient suffers from schizophrenia or depression or bipolar disorder -

Exclusion Criteria:aged\<18or aged\>65

-

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Institute of mental health, Peking University
state: Beijing
Study officials:
affiliation: Peking University
name: Xin Yu, MD.
role: STUDY_CHAIR
References:
Clinical trial NCT03487510: Dysphagia on the Intensive Care Unit
Official title: Dysphagia on the Intensive Care Unit - a Multinational European Analysis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Deglutition Disorders
Keywords: treatment standards
diagnostical approaches
descriptive
Lead sponsor: Insel Gruppe AG, University Hospital Bern
Sponsor class: OTHER
First posted: 2018-04-04
Enrollment: 49
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Senior local ICU physicians (Swiss ICUs only).

Brief summary: Recording of routine practice patterns to detect and/or treat Dysphagia on the ICU via interview of local colleagues. This will not allow to record generalizable data, but will reflect the actual routine standard of care.


Eligibility criteria: Inclusion criteria:

* All senior ICU physicians in charge for adult critically ill ICU patients. Respective ICUs must be accredited by the "Schweizerische Gesellschaft für Intensivmedizin".
* ICUs located in Switzerland.
* Senior ICU physicians willing to voluntarily fill in the provided questionnaire.

Primary outcomes:
measure: Number of centers using fibre-optic endoscopic evaluation of swallowing (FEES) vs. non-instrumental methods to detect/ treat dysphagia on the ICU.
timeFrame: through study completion, an average of 1 month
Secondary outcomes:
Other outcomes:
Locations:
city: Bern
country: Switzerland
facility: Dept. of Intensive Care Medicine, University of Bern,
Study officials:
affiliation: Inselspital, University of Bern
name: Patrick Zürcher, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01605110: Effects of Hyperbaric Oxygen Therapy on Surgical Wound Healing
Official title: Effects of HBOT for Edema/Ecchymosis After Upper Eyelid Blepharoplasty (Single Site Study)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Edema
Ecchymosis
Keywords: blepharoplasty
hyperbaric
oxygen
ecchymosis
edema
wound
healing
Lead sponsor: Restorix Research Institute, LLLP
Sponsor class: OTHER
First posted: 2012-05-24
Enrollment: 164
Sex: ALL
Minimum age (years): 40
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The aim of this study is to test the effect of Hyperbaric Oxygen Therapy) HBOT (100% oxygen; 2.0 ATA; 90 minute total exposure) and compare against a hyperbaric sham treatment (HBST) (patient's breathing room air; 2.0 ATA; 90 minute exposure) in reducing edema and ecchymosis. HBOT will be applied as a single pre-operative and a single post-operative treatment for patients undergoing eyelid surgery. Briefly, patients will be exposed to HBOT 2-4 hours prior to undergoing surgery, 2-4 hours post-surgery and healing will be assessed at day 3, 10, 21, 30 \& 90 days after surgery. Edema and ecchymosis will be assessed in a time series to determine the extent that HBOT reduces these clinical signs. The primary null hypothesis to test will be that no differences in scores will exist between treatment and control at day 3, 10 \& 21 post-surgery. A secondary null hypothesis to test is the time required to change a score will be no different between the two groups.

HBOT=hyperbaric oxygen therapy; HBST=hyperbaric sham treatment


Eligibility criteria: Inclusion Criteria:

* Patients that are able to undergo surgery at the Allure Clinic are capable of undergoing exposure to HBOT, as the contraindications of HBOT are similar to eyelid surgery, with few exceptions.

Exclusion Criteria:

* The investigators will exclude active smokers and those who have quit smoking in the last 12 months, those with known lung disease, seizure disorder, congestive heart failure, known active cancer, previous treatment with specific chemotherapy agents (Doxorubicin, Bleomycin, Disulfiram, Cis-platinum, Mafenide acetate), those who cannot undergo pressurization/ depressurization because of eustachian-tube dysfunction and confinement anxiety.

Primary outcomes:
measure: A measureable reduction of ecchymosis grade in treatment group vs. control group
timeFrame: 21 days
Secondary outcomes:
measure: A measureable reduction of edema grade in treatment group vs. control group
timeFrame: 21 days
Other outcomes:
Locations:
city: Issaquah
country: United States
facility: Restorix Research Institute
state: Washington
Study officials:
affiliation: Allure Laser Center & Medispa
name: Bryan Sires, MD, FACS
role: PRINCIPAL_INVESTIGATOR
References: